What this Trial Is About

Researchers are evaluating two blood tests, eLIFT and FibroMeter, to screen for advanced liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and/or alcoholic liver disease (ALD) in primary care settings. These chronic liver diseases are common and can lead to serious complications if advanced fibrosis is not detected early. General practitioners often find it challenging to identify patients with advanced fibrosis because routine exams and tests may appear normal. The study compares the eLIFT test, designed for easy use by general practitioners with simple calculation, to the more specialized FibroMeter test. Both tests are blood-based and aim to detect advanced liver fibrosis. Patients may also undergo elastography, a device-based liver stiffness measurement, or liver biopsy if needed. The study is conducted in primary care centers where patients with NAFLD and/or ALD will be screened using these tests. Participants provide blood samples and undergo clinical evaluations during the study. Researchers will measure how sensitive each test is in detecting advanced liver fibrosis. The study includes collecting blood samples at local laboratories and monitoring outcomes such as test sensitivity on the same day. The total participation timeframe includes initial screening and diagnostic testing procedures within one day.

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD And/or Alcoholic Patients